Company Profile

Shire specializes in developing, producing, and marketing pharmaceutical products for the treatment of nervous system dysfunctions (hyperactivity, epilepsy, Alzheimer's disease, etc.), cancer, gastro-intestinal illnesses, and infectious diseases. Net sales break down by source of income as follows: - sales of products (95.3%); - other (4.7%): primarily franchise royalties. Net sales break down geographically as follows: the United States (63.6%), Ireland (0.4%) and other (36%).

Employees

Sector

Pharmaceuticals

More about the company

21/12/18	S&P 500 : Dealmakers brace for slowdown after third-strongest M&A year	RE
21/12/18	Asia M&A clocks second best on record, strength to persist despite trade troubles	RE

21/12/18	S&P 500 : Dealmakers brace for slowdown after third-strongest M&A year	RE
21/12/18	Asia M&A clocks second best on record, strength to persist despite trade troubles	RE
20/12/18	British shares falter as Fed, oil play Scrooge	RE
19/12/18	FTSE : GSK pulls FTSE 100 out of three-day rut, focus on Fed	RE
18/12/18	FTSE : Oil slide and growth worries smother FTSE 100 while mid-caps bounce	RE
17/12/18	FTSE : down sharply as ASOS profit alert sparks wider retail selloff	RE
07/12/18	FTSE : Oil helps FTSE 100 end turbulent week firmer, but Brexit weighs	RE
05/12/18	FTSE : falls as growth angst spreads	RE
05/12/18	Growth and trade nerves grind European shares down to two-week low	RE
05/12/18	Takeda Pharmaceutical : clears key hurdle as investors back $59 billion Shire deal	RE
05/12/18	Takeda Pharmaceutical : investors back $59 billion Shire deal, but wary of debt load	RE
21/11/18	Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition	RE
21/11/18	Takeda Pharmaceutical : Investor advisory firms back Takeda's $62 billion deal for Shire	RE

13/05/20	Takeda Pharmaceutical : Drugmaker Takeda expects 35% rise in net profit on lower buyout costs	AQ
04/02/20	Takeda Pharmaceutical : lifts FY 2019 earnings projections after Shire buyout	AQ
07/01/19	Shire : Form 8.3 - Takeda Pharmaceutical	PU
07/01/19	Shire : Form 8.3 -	PU
07/01/19	Shire : Form 8.5 (EPT/RI) - Replacement of Shire	PU

08/01/19	EN DIRECT DES MARCHES : Nissan, Dassault Aviation, STMicroelectronics, Sika, Samsung, Tessi...
07/01/19	Les affaires reprennent dans la pharmacie
21/12/18	Walt Disney : Le marché du M&A se prépare à une année 2019 moins faste
18/12/18	Shire : plombé par le déclassement de Takeda
05/12/18	Altran Technologies : Les craintes sur les taux et le commerce font plier les actions en Europe

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-1.37%	+8.90%	+91.28%	+130.00%	1,083B
JOHNSON & JOHNSON	-0.77%	+1.91%	+49.46%	+49.44%	626B
ABBVIE INC.	+0.85%	+2.58%	+25.90%	+64.34%	442B
ROCHE HOLDING AG	-1.60%	-0.14%	+47.81%	+37.51%	363B
NOVARTIS AG	-1.30%	-0.22%	+29.04%	+36.58%	295B
ASTRAZENECA PLC	-1.11%	-2.57%	+5.78%	+5.52%	248B
AMGEN INC.	-0.70%	+6.23%	+45.32%	+57.82%	224B
NOVO NORDISK A/S	-2.42%	+2.16%	-6.19%	-51.45%	210B
GILEAD SCIENCES, INC.	+2.04%	+0.38%	+12.70%	+69.71%	168B
Average	-0.71%	+1,662.85%	+33.46%	+44.38%	406.57B
Weighted average by Cap.	-0.86%	+1,332.62%	+49.09%	+65.55%

Shire Stock CBOE

Stocks

SHP

JE00B2QKY057

Pharmaceuticals

Latest news : Shire

Analysts' recommendations: Shire

Press Releases: Shire

News in other languages: Shire

Other Pharmaceuticals

Company Profile

End-of-day quote CBOE Other stock markets
- ^GBX	-